Article

Nanotechnology: a focus on nanoparticles as a drug delivery system.

Center for Neurovirology and Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE 68198-5215, USA.
Journal of Neuroimmune Pharmacology (Impact Factor: 3.17). 10/2006; 1(3):340-50. DOI: 10.1007/s11481-006-9032-4
Source: PubMed

ABSTRACT This review will provide an in-depth discussion on the previous development of nanoparticle-based drug delivery systems (DDS) and discuss original research data that includes the therapeutic enhancement of antiretroviral therapy. The use of nanoparticle DDS will allow practitioners to use drugs to target specific areas of the body. In the treatment of malignancies, the use of nanoparticles as a DDS is making measurable treatment impact. Medical imaging will also utilize DDS to illuminate tumors, the brain, or other cellular functions in the body. The utility of nanoparticle DDS to improve human health is potentially enormous.

2 Followers
 · 
227 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer is characterized by anomalous cell growth. Conventional therapies face many challenges and hence alternative treatment methods are in great demand. In addition, nature offers the best inspiration and recently many therapies of natural origin have proved multi-targeted, multi-staged, and a multi-component mode of action against cancer. Magnetotactic bacteria and magnetosomes-based treatment methods are among them. Present paper reviews various routes by which magnetotactic bacteria and magnetosomes contribute to cancer therapy.
    Biotechnology Letters 11/2014; 37(3). DOI:10.1007/s10529-014-1728-6 · 1.74 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In the present study, haloperidol (HP)-loaded solid lipid nanoparticles (SLNs) were prepared to enhance the uptake of HP to brain via intranasal (i.n.) delivery. SLNs were prepared by a modified emulsification–diffusion technique and evaluated for particle size, zeta potential, drug entrapment efficiency, in vitro drug release, and stability. All parameters were found to be in an acceptable range. In vitro drug release was found to be 94.16±4.78% after 24 h and was fitted to the Higuchi model with a very high correlation coefficient (R2=0.9941). Pharmacokinetics studies were performed on albino Wistar rats and the concentration of HP in brain and blood was measured by high performance liquid chromatography. The brain/blood ratio at 0.5 h for HP-SLNs i.n., HP sol. i.n. and HP sol. i.v. was 1.61, 0.17 and 0.031, respectively, indicating direct nose-to-brain transport, bypassing the blood–brain barrier. The maximum concentration (Cmax) in brain achieved from i.n. administration of HP-SLNs (329.17±20.89 ng/mL, Tmax 2 h) was significantly higher than that achieved after i.v. (76.95±7.62 ng/mL, Tmax 1 h), and i.n. (90.13±6.28 ng/mL, Tmax 2 h) administration of HP sol. The highest drug-targeting efficiency (2362.43%) and direct transport percentage (95.77%) was found with HP-SLNs as compared to the other formulations. Higher DTE (%) and DTP (%) suggest that HP-SLNs have better brain targeting efficiency as compared to other formulations.Graphical abstractThe study indicates that SLNs represent a robust drug brain specific delivery system to overcome the blood–brain barrier via i.n. route. Ultimately, the current work may provide a successful concept for clinical application of HP via i.n. route in the treatment of psychiatric conditions like schizophrenia in the future. KEY WORDSBrain targetingHaloperidolIntranasal routePharmacokineticsSolid lipid nanoparticles
    11/2014; DOI:10.1016/j.apsb.2014.10.005
  • [Show abstract] [Hide abstract]
    ABSTRACT: A mathematical model is developed to describe the trajectories of a cluster of magnetic nanoparticles in a blood vessel for the application of magnetic drug targeting (MDT). The magnetic nanoparticles are injected into a blood vessel upstream from a malignant tissue and are captured at the tumour site with help of an applied magnetic field. The applied field is produced by a rare earth cylindrical magnet positioned outside the body. All forces expected to significantly affect the transport of nanoparticles were incorporated, including magnetization force, drag force and buoyancy force. The results show that particles are slow down and captured under the influence of magnetic force, which is responsible to attract the magnetic particles towards the magnet. It is optimized that all particles are captured either before or at the centre of the magnet (z≤0) when blood vessel is very close proximity to the magnet (d=2.5 cm). However, as the distance between blood vessel and magnet (d) increases (above 4.5 cm), the magnetic nanoparticles particles become free and they flow away down the blood vessel. Further, the present model results are validated by the simulations performed using the finite element based COMSOL software.
    Journal of Magnetism and Magnetic Materials 04/2015; 379. DOI:10.1016/j.jmmm.2014.12.012 · 2.00 Impact Factor

Full-text

Download
19 Downloads
Available from
Aug 4, 2014

Similar Publications